|Articles|June 5, 2023

Celebrating Pride Month 2023

June is Pride Month. Psychiatric Times® celebrates with a look at some recent features focused on how clinicians can provide better care for LGBTQ+ patients.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Unified Treatment Model Shows Long-Term Symptom Gains in BIPOC Patients With Eating Disorders

ByLeah Kuntz

July 31st 2026

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

ByAshley A. Mulvihill, MD ,Susan Hatters Friedman, MD, MSt, DFAPA

July 17th 2026

Zuranolone in the Room: Closing the Gap in Postpartum Depression Care

ByLeslie Williams, MD

July 16th 2026

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS

ByEmrys Fonseca, MD, MS

June 25th 2026

Presenting Our June 2026 Theme: Special Populations

ByLeah Kuntz

June 1st 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Celebrating Pride Month 2023

Related Content

Unified Treatment Model Shows Long-Term Symptom Gains in BIPOC Patients With Eating Disorders

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

Zuranolone in the Room: Closing the Gap in Postpartum Depression Care

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS

Presenting Our June 2026 Theme: Special Populations

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jersey City Psychiatry

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FAQ: What Clinicians Need to Know About Postpartum Psychosis

Psychiatry Mid-Year Market Update 2026: Persistent Demand, Widening Valuation Gap, and Workforce/Regulatory Realities

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs